{56 (elexacaftor 100 MG / ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor... — RxCUI 2257013
RxNorm drug concept · Brand name pack
RxCUI 2257013
Brand name pack · BPCK
● Current RxNorm concept 4 FDA products
4 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2257013
Official name{56 (elexacaftor 100 MG / ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 150 MG Oral Tablet) } Pack [Trikafta (100 MG / 50 MG / 75 MG; 150 MG)]
Concept typeBrand name pack (BPCK)
RxNorm statusCurrent RxNorm concept
Also known astrikafta 100 MG / 50 MG / 75 MG and 150 MG Tablet Pack
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)51,835 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Ivacaftor: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Kalydeco doesn't cure cystic fibrosis, but it targets the root cause in people with certain gene mutations. It helps a faulty protein in your cells — called CFTR — work better by k...
- What exactly does Kalydeco do for cystic fibrosis — does it cure it?
- It really does matter what you take it with. Fat in food increases how much ivacaftor your body absorbs — by as much as 2.5 to 4 times. Taking it with just water means you're likel...
- Why does it have to be taken with food? Can I just take it with water?
🕸️ Concept Web — How {56 (elexacaftor 100 MG / ivacaftor 75 MG / teza... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
{56 (elexacaftor 100 MG / ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 150 MG Oral Tablet) } Pack [Trikafta (100 MG / 50 MG / 75 MG; 150 MG)]
RxCUI 2257013 Brand name pack · BPCK
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 4
The active substance itself — no strength, form, or brand attached yet.
-
Elexacaftor
2256951IN -
Ivacaftor
1243041IN -
Tezacaftor
1999382IN -
Elexacaftor / ivacaftor / tezacaftor
2257010MIN
-
Elexacaftor
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Elexacaftor / ivacaftor / tezacaftor Oral Tablet
2257009SCDF -
Ivacaftor Oral Tablet
1243045SCDF -
Elexacaftor / ivacaftor / tezacaftor Oral Product
2257007SCDG -
Elexacaftor / ivacaftor / tezacaftor Pill
2257008SCDG -
Ivacaftor Oral Product
1243043SCDG -
Ivacaftor Pill
1243044SCDG -
Pack
746839DF -
Oral Product
1151131DFG - +1 more in this family
-
Elexacaftor / ivacaftor / tezacaftor Oral Tablet
-
Clinical & branded drugs 6
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Elexacaftor 100 MG / ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet
2257011SCD -
Ivacaftor 150 MG Oral Tablet
1243046SCD -
Elexacaftor 100 MG
2257006SCDC -
Ivacaftor 150 MG
1243042SCDC -
Ivacaftor 75 MG
1606867SCDC -
Tezacaftor 50 MG
2174386SCDC
-
Elexacaftor 100 MG / ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet
-
Packs 1
Fixed collections of drugs packaged and sold together, like dose packs.
Showing up to 8 concepts per family — 19 of 20 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Elexacaftor 100 MG / ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet
SCD · 2257011 -
Ivacaftor 150 MG Oral Tablet
SCD · 1243046 -
{56 (elexacaftor 100 MG / ivacaftor 75 MG / tezacaftor 50 MG Oral Tablet) / 28 (ivacaftor 150 MG Oral Tablet) } Pack
GPCK · 2257012 -
Elexacaftor 100 MG
SCDC · 2257006 -
Ivacaftor 150 MG
SCDC · 1243042 -
Ivacaftor 75 MG
SCDC · 1606867 -
Tezacaftor 50 MG
SCDC · 2174386 -
Elexacaftor / ivacaftor / tezacaftor Oral Tablet
SCDF · 2257009 -
Ivacaftor Oral Tablet
SCDF · 1243045 -
Elexacaftor / ivacaftor / tezacaftor Oral Product
SCDG · 2257007
📦 FDA Products & Package NDCs
4 products · 4 package NDCs
4 package NDCs map to RxCUI 2257013 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 51167-0106-02 | 4 BLISTER PACK in 1 CARTON (51167-106-02) / 1 KIT in 1 BLIS... | Trikafta | Vertex Pharmaceuticals Incorporated | 2021-06-08 |
| 51167-0331-01 | 4 BLISTER PACK in 1 CARTON (51167-331-01) / 1 KIT in 1 BLIS... | Trikafta | Vertex Pharmaceuticals Incorporated | 2019-10-21 |
| 51167-0445-01 | 4 PACKAGE in 1 CARTON (51167-445-01) / 1 KIT in 1 PACKAGE *... | Trikafta | Vertex Pharmaceuticals Incorporated | 2023-04-26 |
| 51167-0446-01 | 4 PACKAGE in 1 CARTON (51167-446-01) / 1 KIT in 1 PACKAGE *... | Trikafta | Vertex Pharmaceuticals Incorporated | 2023-04-26 |
Observed labelers:
Vertex Pharmaceuticals Incorporated (4)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.